Shield Therapeutics, a Switzerland-based specialty pharmaceutical company treating iron deficiency in the blood, has raised €8.2m ($12m) from Inventages Venture Capital, which acts as the corporate venturing unit for local chocolate maker Nestle, in its series A round. The round gives a post-money valuation of €35m and will be paid in two equal tranches…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
